Stock MXCT MAXCYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company MaxCyte, Inc.

Equities

MXCT

US57777K1060

Advanced Medical Equipment & Technology

Delayed London S.E.
Other stock markets
 03:05:12 2024-04-16 am EDT 		5-day change 1st Jan Change
310.1 GBX -1.56% Intraday chart for MaxCyte, Inc. -6.03% -12.03%
Apr. 02 MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines CI
Mar. 13 BTIG Adjusts Price Target on MaxCyte to $8 From $10, Maintains Buy Rating MT

Business Summary

MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.

Number of employees: 143

Sales per Business

USD in Million2022Weight2023Weight Delta
Cell Therapy
55.3 %
31 69.0 % 23 55.3 % -25.26%
Program-related
27.8 %
5 10.4 % 11 27.8 % +148.38%
Drug Discovery
16.9 %
9 20.6 % 7 16.9 % -23.14%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
44 100.0 % 41 100.0 % -6.72%

Managers

Managers TitleAgeSince
Maher Masoud CEO
 Chief Executive Officer 49 -
Douglas Swirsky DFI
 Director of Finance/CFO 54 23-03-26
James Brady CTO
 Chief Tech/Sci/R&D Officer - -
Ron Holtz ADM
 Chief Administrative Officer 66 04-12-31
Ali Soleymannezhad PRN
 Corporate Officer/Principal - 23-08-20
Gene Zhu LAW
 General Counsel - -
Jill Mayer HRO
 Human Resources Officer - 17-12-31
Thomas Ross SAM
 Sales & Marketing 63 14-10-14
Steven Nardi PRN
 Corporate Officer/Principal - 20-10-12

Members of the board

Members of the board TitleAgeSince
Patrick Balthrop BRD
 Director/Board Member 67 22-11-30
Art Mandell BRD
 Director/Board Member 71 06-04-30
Will Brooke BRD
 Director/Board Member 68 04-02-29
Stanley Erck BRD
 Director/Board Member 76 04-12-31
Ron Holtz ADM
 Chief Administrative Officer 66 04-12-31
John Johnston BRD
 Director/Board Member 65 15-12-31
Richard Douglas CHM
 Chairman 71 18-02-11
Yasir Al-Wakeel BRD
 Director/Board Member 42 21-06-14
Rekha Hemrajani BRD
 Director/Board Member 54 21-06-14
Maher Masoud CEO
 Chief Executive Officer 49 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 104,128,650 97,898,738 ( 94.02 %) 0 94.02 %

Shareholders

NameEquities%Valuation
BlackRock Fund Advisors
7.976 %
8,305,448 7.976 % 35 M p
BlackRock Advisors LLC
6.665 %
6,940,295 6.665 % 29 M p
Millennium Management LLC
5.521 %
5,749,015 5.521 % 24 M p
Cadian Capital Management LP
5.421 %
5,644,898 5.421 % 24 M p
Vanguard Fiduciary Trust Co.
5.073 %
5,282,108 5.073 % 22 M p
Vitruvian Partners LLP
4.843 %
5,043,356 4.843 % 21 M p
Millennium Management LLC
4.814 %
5,012,283 4.814 % 21 M p
Sofinnova Partners SAS
4.428 %
4,610,693 4.428 % 19 M p
Morgan Stanley Investment Management, Inc.
3.343 %
3,481,010 3.343 % 15 M p
Fidelity Management & Research Co. LLC
2.721 %
2,833,715 2.721 % 12 M p

Company contact information

MaxCyte, Inc.

9713 Key West Avenue Suite 400

20850, Rockville

+301 944 1700

http://www.maxcyte.com
address MaxCyte, Inc.(MXCT)

Sector

Healthcare
Healthcare Services
Healthcare Equipment & Supplies
Advanced Medical Equipment & Technology
Other Advanced Medical Equipment & Technology

Sales per Business

Ratings for MaxCyte, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.108 USD
Average target price
9.631 USD
Spread / Average Target
+134.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
MAXCYTE, INC. Stock MaxCyte, Inc.
-10.64% 429M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+5.10% 216B
DANAHER CORPORATION Stock Danaher Corporation
+3.60% 178B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.89% 136B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+16.66% 100B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+1.71% 63.38B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+16.98% 54.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-4.51% 45.22B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+0.86% 41.24B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.39% 39.37B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. MXCT Stock
  4. Company MaxCyte, Inc.